Covered recipient · General Payments record
ROBERT I HADDAD
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$111,352.45
81 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $52,094.43 | 16 |
| Travel and Lodging | $49,621.28 | 33 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,680.00 | 1 |
| Food and Beverage | $1,956.74 | 31 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Merck Sharp & Dohme LLC | $56,080.60 | 45 |
| Exelixis Inc. | $10,119.64 | 7 |
| GlaxoSmithKline, LLC. | $8,236.75 | 7 |
| Genmab U.S., Inc. | $8,121.51 | 2 |
| Hikma Pharmaceuticals USA | $7,732.65 | 6 |
| Boehringer Ingelheim International GmbH | $4,800.00 | 2 |
| ABBVIE INC. | $3,693.00 | 2 |
| E.R. Squibb & Sons, L.L.C. | $3,081.46 | 3 |
| Janssen Scientific Affairs, LLC | $2,643.75 | 2 |
| AstraZeneca UK Limited | $2,460.00 | 1 |
| Janssen Research & Development, LLC | $2,220.00 | 1 |
| AstraZeneca Pharmaceuticals LP | $1,458.09 | 2 |
| Janssen Pharmaceuticals, Inc | $705.00 | 1 |
Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ROBERT I HADDAD
NPI 1942259098 · CMS profile ID 88160
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
BOSTON, MA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1942259098?year=2025&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ROBERT I HADDAD, NPI 1942259098, CMS profile ID 88160. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1942259098?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). ROBERT I HADDAD, NPI 1942259098, CMS profile ID 88160. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1942259098?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- ROBERT I HADDAD, NPI 1942259098, CMS profile ID 88160, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1942259098?year=2025&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
81 matching records · $111,352.45 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–81 of 81.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Exelixis Inc. | $58.00 | 06/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218802289 | CMS |
| Exelixis Inc. | $9,337.24 | 06/10/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218802281 | CMS |
| E.R. Squibb & Sons, L.L.C. | $125.92 | 05/31/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184518487 | CMS |
| E.R. Squibb & Sons, L.L.C. | $15.54 | 05/31/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184518489 | CMS |
| ABBVIE INC. | $68.00 | 05/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1201986935 | CMS |
| GlaxoSmithKline, LLC. | $52.41 | 05/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1190625614 | CMS |
| GlaxoSmithKline, LLC. | $190.63 | 05/15/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1190568248 | CMS |
| Merck Sharp & Dohme LLC | $8,960.00 | 05/14/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1237994832 | CMS |
| Merck Sharp & Dohme LLC | $150.00 | 05/14/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238002150 | CMS |
| Merck Sharp & Dohme LLC | $32.01 | 05/09/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238001200 | CMS |
| Merck Sharp & Dohme LLC | $44.89 | 05/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238002350 | CMS |
| Merck Sharp & Dohme LLC | $29.93 | 05/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238033418 | CMS |
| Merck Sharp & Dohme LLC | $215.70 | 05/09/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238038840 | CMS |
| Merck Sharp & Dohme LLC | $215.70 | 05/08/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1237998046 | CMS |
| Merck Sharp & Dohme LLC | $67.84 | 05/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1237999206 | CMS |
| Merck Sharp & Dohme LLC | $69.85 | 05/08/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238010724 | CMS |
| Merck Sharp & Dohme LLC | $215.70 | 05/07/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1237998048 | CMS |
| Merck Sharp & Dohme LLC | $7,360.91 | 05/07/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1237998790 | CMS |
| Merck Sharp & Dohme LLC | $5,760.00 | 05/07/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238036260 | CMS |
| Merck Sharp & Dohme LLC | $150.00 | 05/07/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238040337 | CMS |
| Genmab U.S., Inc. | $8,090.68 | 05/01/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235925837 | CMS |
| GlaxoSmithKline, LLC. | $31.41 | 04/30/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1190404935 | CMS |
| GlaxoSmithKline, LLC. | $620.83 | 04/30/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1190460880 | CMS |
| Merck Sharp & Dohme LLC | $183.07 | 04/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238269276 | CMS |
| AstraZeneca UK Limited | $2,460.00 | 04/01/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211398780 | CMS |
| Boehringer Ingelheim International GmbH | $740.00 | 03/07/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1215873473 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,370.00 | 02/25/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1214772817 | CMS |
| Genmab U.S., Inc. | $30.83 | 01/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235925833 | CMS |
| Merck Sharp & Dohme LLC | $1,220.00 | 01/27/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238039396 | CMS |
| Janssen Pharmaceuticals, Inc | $705.00 | 01/23/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174533703 | CMS |
| Janssen Scientific Affairs, LLC | $881.25 | 01/23/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174170514 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $1,720.29 | 1 |
| PY2025 | Principal investigator | $967,878.05 | 66 |
| PY2024 | Recipient | $44,959.22 | 13 |
| PY2024 | Principal investigator | $593,712.39 | 44 |
| PY2023 | Principal investigator | $745,226.54 | 127 |
| PY2022 | Principal investigator | $685,220.86 | 18 |
| PY2021 | Principal investigator | $613,536.37 | 25 |
| PY2020 | Principal investigator | $176,630.74 | 53 |
| PY2019 | Recipient | $5,732.00 | 1 |
| PY2019 | Principal investigator | $293,247.83 | 69 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
67 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $8,500.03 | 12/31/2025 | Non-covered Recipient Entity DANA FARBER CANCER INSTITUTE, INC | A Phase III, Randomized,Open Label,Multi Center,Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma,Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy | No dispute reported | 06/30/2026 | 1185546601 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $7,436.54 | 12/31/2025 | Non-covered Recipient Entity Dana Farber Cancer Institute | A Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab MK3475 with or without lenvatinib E7080,MK-7902 to evaluate the safety and efficacy of pembrolizumab and lenvatinib as 1L intervention in a PD-L1 selected populati | No dispute reported | 06/30/2026 | 1232917493 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $17,540.72 | 12/31/2025 | Non-covered Recipient Entity Dana Farber Cancer Center | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC | No dispute reported | 06/30/2026 | 1232927059 |
| Principal investigator 1 | Incyte Corporation | $715.50 | 12/24/2025 | Non-covered Recipient Entity Dana Farber Mass General Brigham Cancer Care Inc | A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | No dispute reported | 06/30/2026 | 1240520917 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $40,090.19 | 12/09/2025 | Non-covered Recipient Entity Dana Farber Cancer Institute | Head And Neck Cancer Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1199911317 |
| Principal investigator 1 | Incyte Corporation | $18,246.00 | 11/24/2025 | Non-covered Recipient Entity Dana Farber Mass General Brigham Cancer Care Inc | A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | No dispute reported | 06/30/2026 | 1240520926 |
| Principal investigator 1 | Incyte Corporation | $34,450.00 | 11/24/2025 | Non-covered Recipient Entity Dana Farber Mass General Brigham Cancer Care Inc | A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | No dispute reported | 06/30/2026 | 1240520930 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $77,244.68 | 11/20/2025 | Non-covered Recipient Entity Dana Farber Cancer Institute | Head And Neck Cancer Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1199911319 |
| Principal investigator 1 | Incyte Corporation | $8,677.00 | 11/06/2025 | Non-covered Recipient Entity Dana Farber Mass General Brigham Cancer Care Inc | A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | No dispute reported | 06/30/2026 | 1240520922 |
| Principal investigator 1 | Incyte Corporation | $8,677.00 | 10/30/2025 | Non-covered Recipient Entity Dana Farber Mass General Brigham Cancer Care Inc | A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | No dispute reported | 06/30/2026 | 1240520913 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $93,575.68 | 10/22/2025 | Non-covered Recipient Entity Dana Farber , Mass General Brigham Cancer Care, Inc | Phase II, multi cohort trial of neoadjuvant and post surgery IO102 IO103 and pembrolizumab in patients with selected resectable tumors | No dispute reported | 06/30/2026 | 1232932165 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $17,603.29 | 10/08/2025 | Non-covered Recipient Entity Dana Farber Cancer Institute | Head And Neck Cancer Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1199911315 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $1,575.00 | 10/08/2025 | Non-covered Recipient Entity Dana Farber Cancer Institute | Head And Neck Cancer Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1199911321 |
| Principal investigator 1 | Exelixis Inc. | $3,000.00 | 10/02/2025 | Non-covered Recipient Entity Dana Farber Cancer Institute | A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1222380458 |
| Principal investigator 1 | Exelixis Inc. | $2,500.00 | 10/02/2025 | Non-covered Recipient Entity Dana Farber Cancer Institute | A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1222380460 |
| Principal investigator 1 | Exelixis Inc. | $8,500.00 | 10/02/2025 | Non-covered Recipient Entity Dana Farber Cancer Institute | A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1222380462 |
| Principal investigator 1 | Exelixis Inc. | $2,500.00 | 10/02/2025 | Non-covered Recipient Entity Dana Farber Cancer Institute | A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1222380464 |
| Principal investigator 1 | Exelixis Inc. | $10,000.00 | 10/02/2025 | Non-covered Recipient Entity Dana Farber Cancer Institute | A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1222380466 |
| Principal investigator 1 | Exelixis Inc. | $3,000.00 | 10/02/2025 | Non-covered Recipient Entity Dana Farber Cancer Institute | A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1222380468 |
| Principal investigator 1 | Exelixis Inc. | $1,000.00 | 10/02/2025 | Non-covered Recipient Entity Dana Farber Cancer Institute | A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1222380470 |
| Principal investigator 1 | Exelixis Inc. | $1,350.00 | 10/02/2025 | Non-covered Recipient Entity Dana Farber Cancer Institute | A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1222380472 |
| Principal investigator 1 | Exelixis Inc. | $4,000.00 | 10/02/2025 | Non-covered Recipient Entity Dana Farber Cancer Institute | A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1222380474 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,500.00 | 09/25/2025 | Non-covered Recipient Entity DANA FARBER CANCER INSTITUTE INC | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY USING A MASTER PROTO | No dispute reported | 06/30/2026 | 1192135635 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,500.00 | 09/25/2025 | Non-covered Recipient Entity DANA FARBER CANCER INSTITUTE INC | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY USING A MASTER PROTO | No dispute reported | 06/30/2026 | 1192135645 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,500.00 | 09/25/2025 | Non-covered Recipient Entity DANA FARBER CANCER INSTITUTE INC | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY USING A MASTER PROTO | No dispute reported | 06/30/2026 | 1192140514 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,500.00 | 09/25/2025 | Non-covered Recipient Entity DANA FARBER CANCER INSTITUTE INC | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY USING A MASTER PROTO | No dispute reported | 06/30/2026 | 1192140526 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,500.00 | 09/25/2025 | Non-covered Recipient Entity DANA FARBER CANCER INSTITUTE INC | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY USING A MASTER PROTO | No dispute reported | 06/30/2026 | 1192140543 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,000.00 | 09/25/2025 | Non-covered Recipient Entity DANA FARBER CANCER INSTITUTE INC | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY USING A MASTER PROTO | No dispute reported | 06/30/2026 | 1192140555 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $26,911.90 | 09/10/2025 | Non-covered Recipient Entity Dana Farber Cancer Institute | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199911289 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $53,327.63 | 09/10/2025 | Non-covered Recipient Entity Dana Farber Cancer Institute | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199911299 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $300.00 | 09/02/2025 | Non-covered Recipient Entity DANA FARBER CANCER INSTITUTE INC | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY USING A MASTER PROTO | No dispute reported | 06/30/2026 | 1192135640 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $150.00 | 09/02/2025 | Non-covered Recipient Entity DANA FARBER CANCER INSTITUTE INC | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY USING A MASTER PROTO | No dispute reported | 06/30/2026 | 1192135652 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $600.00 | 09/02/2025 | Non-covered Recipient Entity DANA FARBER CANCER INSTITUTE INC | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY USING A MASTER PROTO | No dispute reported | 06/30/2026 | 1192135660 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $450.00 | 09/02/2025 | Non-covered Recipient Entity DANA FARBER CANCER INSTITUTE INC | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY USING A MASTER PROTO | No dispute reported | 06/30/2026 | 1192140521 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $600.00 | 09/02/2025 | Non-covered Recipient Entity DANA FARBER CANCER INSTITUTE INC | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY USING A MASTER PROTO | No dispute reported | 06/30/2026 | 1192140530 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $450.00 | 09/02/2025 | Non-covered Recipient Entity DANA FARBER CANCER INSTITUTE INC | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY USING A MASTER PROTO | No dispute reported | 06/30/2026 | 1192140536 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $300.00 | 09/02/2025 | Non-covered Recipient Entity DANA FARBER CANCER INSTITUTE INC | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY USING A MASTER PROTO | No dispute reported | 06/30/2026 | 1192140548 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $21,042.00 | 08/06/2025 | Non-covered Recipient Entity Dana Farber Cancer Institute | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199911301 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $18,230.40 | 07/31/2025 | Non-covered Recipient Entity Dana Farber Cancer Institute | A Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab MK3475 with or without lenvatinib E7080,MK-7902 to evaluate the safety and efficacy of pembrolizumab and lenvatinib as 1L intervention in a PD-L1 selected populati | No dispute reported | 06/30/2026 | 1232917491 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $43,697.29 | 07/25/2025 | Non-covered Recipient Entity DANA FARBER PARTNERS CANCER CARE | A Phase III, Randomized,Open Label,Multi Center,Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma,Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy | No dispute reported | 06/30/2026 | 1185546599 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $36,342.20 | 07/16/2025 | Non-covered Recipient Entity Dana Farber Cancer Institute | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199911291 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $26,640.73 | 07/09/2025 | Non-covered Recipient Entity Dana Farber Cancer Institute | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199911303 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $48,918.12 | 06/20/2025 | Non-covered Recipient Entity Dana Farber Cancer Institute | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199911311 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $56,007.03 | 06/04/2025 | Non-covered Recipient Entity DANA FARBER CANCER INSTITUTE INC. | A Phase III, Randomized,Open Label,Multi Center,Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma,Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy | No dispute reported | 06/30/2026 | 1185546603 |
| Principal investigator 1 | Incyte Corporation | $13,354.00 | 05/22/2025 | Non-covered Recipient Entity DANA-FARBER CANCER CENTER | A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | No dispute reported | 06/30/2026 | 1240520427 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $33,223.50 | 05/13/2025 | Non-covered Recipient Entity Dana Farber Cancer Institute | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199911305 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $24,248.14 | 05/13/2025 | Non-covered Recipient Entity Dana Farber Cancer Institute | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199911313 |
| Principal investigator 1 | Incyte Corporation | $25.02 | 05/08/2025 | Non-covered Recipient Entity DANA-FARBER CANCER CENTER | A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | No dispute reported | 06/30/2026 | 1240520431 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $875.00 | 04/17/2025 | Non-covered Recipient Entity Dana Farber Cancer Institute | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199911307 |
| Principal investigator 1 | Incyte Corporation | $9,297.90 | 04/17/2025 | Non-covered Recipient Entity DANA-FARBER CANCER CENTER | A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | No dispute reported | 06/30/2026 | 1240520423 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $17,481.75 | 04/11/2025 | Non-covered Recipient Entity Dana Farber Cancer Institute | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199911309 |
| Recipient | F. Hoffmann-La Roche AG | $1,720.29 | 03/31/2025 | Covered Recipient Physician | Atezolizumab versus placebo as adjuvant therapy in locally advanced head and neck cancer | No dispute reported | 06/30/2026 | 1211538583 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $20,840.31 | 03/19/2025 | Non-covered Recipient Entity Dana Farber Cancer Institute | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199911297 |
| Principal investigator 1 | Genentech, Inc. | $18,010.00 | 03/14/2025 | Non-covered Recipient Entity DANA FARBER CANCER INSTITUTE INC | Atezolizumab versus placebo as adjuvant therapy in locally advanced head and neck cancer | No dispute reported | 06/30/2026 | 1211593800 |
| Principal investigator 1 | Genentech, Inc. | $2,566.00 | 03/14/2025 | Non-covered Recipient Entity DANA FARBER CANCER INSTITUTE INC | Atezolizumab versus placebo as adjuvant therapy in locally advanced head and neck cancer | No dispute reported | 06/30/2026 | 1211593804 |
| Principal investigator 1 | Genentech, Inc. | $10,300.00 | 03/14/2025 | Non-covered Recipient Entity DANA FARBER CANCER INSTITUTE INC | Atezolizumab versus placebo as adjuvant therapy in locally advanced head and neck cancer | No dispute reported | 06/30/2026 | 1211593807 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $700.00 | 03/06/2025 | Non-covered Recipient Entity Dana Farber Cancer Institute | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199911287 |
| Principal investigator 1 | Incyte Corporation | $18,246.00 | 02/27/2025 | Non-covered Recipient Entity Dana Farber Mass General Brigham Cancer Care Inc | A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | No dispute reported | 06/30/2026 | 1240520905 |
| Principal investigator 1 | Incyte Corporation | $10,659.60 | 02/13/2025 | Non-covered Recipient Entity Dana Farber Mass General Brigham Cancer Care Inc | A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | No dispute reported | 06/30/2026 | 1240520909 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $875.00 | 02/05/2025 | Non-covered Recipient Entity Dana Farber Cancer Institute | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199911285 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $29,769.36 | 02/05/2025 | Non-covered Recipient Entity Dana Farber Cancer Institute | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199911295 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $1,153.40 | 02/05/2025 | Non-covered Recipient Entity Dana Farber Cancer Center | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC | No dispute reported | 06/30/2026 | 1232926885 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $8,597.10 | 01/22/2025 | Non-covered Recipient Entity Dana Farber Cancer Institute | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199911283 |
| Principal investigator 1 | Incyte Corporation | $12,789.90 | 01/16/2025 | Non-covered Recipient Entity Dana Farber Mass General Brigham Cancer Care Inc | A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | No dispute reported | 06/30/2026 | 1240520902 |
| Principal investigator 1 | Incyte Corporation | $75.06 | 01/09/2025 | Non-covered Recipient Entity DANA-FARBER/ MASS GENERAL | A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | No dispute reported | 06/30/2026 | 1240520843 |
| Principal investigator 1 | Incyte Corporation | $100.08 | 01/09/2025 | Non-covered Recipient Entity DANA-FARBER/ MASS GENERAL | A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | No dispute reported | 06/30/2026 | 1240520847 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $21,042.00 | 01/08/2025 | Non-covered Recipient Entity Dana Farber Cancer Institute | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199911293 |